These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 29033567)

  • 21. Advances in the research of nanodrug delivery system for targeted treatment of liver fibrosis.
    Peng W; Cheng S; Bao Z; Wang Y; Zhou W; Wang J; Yang Q; Chen C; Wang W
    Biomed Pharmacother; 2021 May; 137():111342. PubMed ID: 33581652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted Drug Delivery to Hepatic Stellate Cells for the Treatment of Liver Fibrosis.
    Chen Z; Jain A; Liu H; Zhao Z; Cheng K
    J Pharmacol Exp Ther; 2019 Sep; 370(3):695-702. PubMed ID: 30886124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development.
    Sung YC; Liu YC; Chao PH; Chang CC; Jin PR; Lin TT; Lin JA; Cheng HT; Wang J; Lai CP; Chen LH; Wu AY; Ho TL; Chiang T; Gao DY; Duda DG; Chen Y
    Theranostics; 2018; 8(4):894-905. PubMed ID: 29463989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic review: hepatic fibrosis - regression with therapy.
    Zois CD; Baltayiannis GH; Karayiannis P; Tsianos EV
    Aliment Pharmacol Ther; 2008 Nov; 28(10):1175-87. PubMed ID: 18761707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reactive Oxygen Species-Responsive Polypeptide Drug Delivery System Targeted Activated Hepatic Stellate Cells to Ameliorate Liver Fibrosis.
    Hao Y; Song K; Tan X; Ren L; Guo X; Zhou C; Li H; Wen J; Meng Y; Lin M; Zhang Y; Huang H; Wang L; Zheng W
    ACS Nano; 2022 Dec; 16(12):20739-20757. PubMed ID: 36454190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipid based nanocarriers for effective drug delivery and treatment of diabetes associated liver fibrosis.
    Salunkhe SA; Chitkara D; Mahato RI; Mittal A
    Adv Drug Deliv Rev; 2021 Jun; 173():394-415. PubMed ID: 33831474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatic stellate cells and the reversal of fibrosis.
    Kisseleva T; Brenner DA
    J Gastroenterol Hepatol; 2006 Oct; 21 Suppl 3():S84-7. PubMed ID: 16958681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemically modified liposomes carrying TRAIL target activated hepatic stellate cells and ameliorate hepatic fibrosis in vitro and in vivo.
    Li Q; Ding Y; Guo X; Luo S; Zhuang H; Zhou J; Xu N; Yan Z
    J Cell Mol Med; 2019 Mar; 23(3):1951-1962. PubMed ID: 30592139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An integrin-based nanoparticle that targets activated hepatic stellate cells and alleviates liver fibrosis.
    Li Y; Pu S; Liu Q; Li R; Zhang J; Wu T; Chen L; Li H; Yang X; Zou M; Xiao J; Xie W; He J
    J Control Release; 2019 Jun; 303():77-90. PubMed ID: 31004666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Research progress of receptor targeted hepatic stellate cell in treatment of liver fibrosis].
    Yang D
    Zhonghua Gan Zang Bing Za Zhi; 2018 Aug; 26(8):630-632. PubMed ID: 30317799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting hepatic stellate cells for cell-specific treatment of liver fibrosis.
    Beljaars L; Meijer DK; Poelstra K
    Front Biosci; 2002 May; 7():e214-22. PubMed ID: 11991830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Golgi Apparatus-Targeted Chondroitin-Modified Nanomicelles Suppress Hepatic Stellate Cell Activation for the Management of Liver Fibrosis.
    Luo J; Zhang P; Zhao T; Jia M; Yin P; Li W; Zhang ZR; Fu Y; Gong T
    ACS Nano; 2019 Apr; 13(4):3910-3923. PubMed ID: 30938986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of nanoparticles to deliver nitric oxide to hepatic stellate cells for treating liver fibrosis and portal hypertension.
    Duong HT; Dong Z; Su L; Boyer C; George J; Davis TP; Wang J
    Small; 2015 May; 11(19):2291-304. PubMed ID: 25641921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic targets in liver fibrosis.
    Fallowfield JA
    Am J Physiol Gastrointest Liver Physiol; 2011 May; 300(5):G709-15. PubMed ID: 21233278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver fibrosis therapy based on biomimetic nanoparticles which deplete activated hepatic stellate cells.
    Xia S; Liu Z; Cai J; Ren H; Li Q; Zhang H; Yue J; Zhou Q; Zhou T; Wang L; Liu X; Zhou X
    J Control Release; 2023 Mar; 355():54-67. PubMed ID: 36693527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vitamin A-decorated biocompatible micelles for chemogene therapy of liver fibrosis.
    Qiao JB; Fan QQ; Xing L; Cui PF; He YJ; Zhu JC; Wang L; Pang T; Oh YK; Zhang C; Jiang HL
    J Control Release; 2018 Aug; 283():113-125. PubMed ID: 29857004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting Hepatic Stellate Cell Death to Reverse Hepatic Fibrosis.
    Zhang X; Zeng Y; Zhao L; Xu Q; Miao D; Yu F
    Curr Drug Targets; 2023; 24(7):568-583. PubMed ID: 36999702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mesenchymal stromal cells in hepatic fibrosis/cirrhosis: from pathogenesis to treatment.
    Yang X; Li Q; Liu W; Zong C; Wei L; Shi Y; Han Z
    Cell Mol Immunol; 2023 Jun; 20(6):583-599. PubMed ID: 36823236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Research advances in the treatment of hepatic fibrosis].
    Xia L; Yang CQ
    Zhonghua Gan Zang Bing Za Zhi; 2017 Aug; 25(8):566-570. PubMed ID: 29056004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral targeted delivery of Imatinib by pH responsive copolymer modulates liver fibrosis in the mice model.
    Siapoush S; Mousazadeh H; Rezaei R; Hatami B; Mazhari S; Hashemi N; Reza Zali M; Baghaei K
    Int J Pharm; 2023 Jun; 641():123068. PubMed ID: 37225027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.